---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-384386"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-09-08T11:39:23+00:00"
generated_at: "2026-09-08T11:40:04.918887+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology appoints Thomas Civik as permanent CEO and Chairman; Flavin becomes Lead Independent Director

## Summary
- Civik, interim CEO since Feb 2026, named permanent CEO and Chairman effective Sept 4, 2026; Flavin transitions to Lead Independent Director.
- New CEO package: $710k base salary, 60% target bonus, $100k sign-on bonus, and option for 2,503,050 shares vesting over 4 years.
- Board member Santhosh Palani resigned Sept 4, 2026; board reduced from 8 to 7 members, with his unvested equity accelerated.
- Company expects updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC in Fall 2026 and Phase 1/2 combo data with pembrolizumab in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-384386
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-09-08T11:39:23+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/0001193125-26-384386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/pyxs-20260903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-384386
- JSON: https://secwatch.observer/filing/0001193125-26-384386.json
- Plain text: https://secwatch.observer/filing/0001193125-26-384386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.